DDInter31 DDInter1376
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Adenosine {u} (Compound) resembles {v} (Compound) Azacitidine
Adenosine {u} (Compound) resembles {v} (Compound) Nelarabine
Adenosine {u} (Compound) binds {v} (Gene) ADORA2B
Adenosine {u} (Compound) is included by {v} (Pharmacologic Class) Adenosine Receptor Agonists
Adenosine {u} (Compound) downregulates {v} (Gene) KIF14
Adenosine {u} (Compound) causes {v} (Side Effect) Atrioventricular block
Adenosine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cilostazol
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Adenosine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Adenosine (Compound) resembles Azacitidine (Compound)
Adenosine (Compound) resembles Nelarabine (Compound)
Adenosine (Compound) binds ADORA2B (Gene)
Adenosine (Compound) is included by Adenosine Receptor Agonists (Pharmacologic Class)
Adenosine (Compound) downregulates KIF14 (Gene)
Adenosine (Compound) causes Atrioventricular block (Side Effect)
Adenosine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Caffeine
Adenosine may lead to a major life threatening interaction when taken with Ribociclib